Development of animal models for the acute respiratory distress syndrome

被引:79
作者
Bastarache, Julie A. [1 ,4 ]
Blackwell, Timothy S. [1 ,2 ,3 ,4 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[4] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA
关键词
ACUTE LUNG INJURY; GLYCATION END-PRODUCTS; BRONCHOALVEOLAR LAVAGE; FIBRIN DEPOSITION; COAGULATION; OUTCOMES; FLUID; ABNORMALITIES; INFLAMMATION; EPITHELIUM;
D O I
10.1242/dmm.001677
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Injury to the lung parenchyma results in the acute respiratory distress syndrome (ARDS), which is a common and life-threatening cause of respiratory failure and mortality that develops after a variety of insults, including sepsis, multiple trauma, pneumonia, aspiration of gastric contents and severe burns. The pathogenesis of ARDS is complex with loss of the alveolar-capillary barrier and flooding of the airspaces with protein-rich fluid; injury to the alveolar epithelium; an influx of neutrophils and macrophages; and fibrin deposition as a result of activation of coagulation and inhibition of fibrinolysis. These changes develop over hours to a few days after the initiating event and often take days or weeks to resolve. Despite decades of research, there is only one therapy (low tidal volume ventilation) that has been shown to reduce mortality in ARDS. Further research into the pathogenesis of this devastating condition is crucial for the development of novel and specific therapies that target specific disease mechanisms. Unfortunately, no single animal model of ARDS replicates the complex pathophysiological changes seen in patients. This is a severe limitation in the study of ARDS and has impaired scientific and therapeutic progress in this field. Here, we discuss the primary features of this syndrome, highlight limitations of current animal models and suggest new approaches to investigate key components of pathogenesis. Hopefully, as new technologies and approaches emerge, barriers to scientific progress in ARDS will be overcome.
引用
收藏
页码:218 / 223
页数:6
相关论文
共 40 条
[1]
*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801
[2]
Lung injury and recovery in a murine model of unilateral acid aspiration: Functional, biochemical, and morphologic characterization [J].
Amigoni, Maria ;
Bellani, Giacomo ;
Scanziani, Margherita ;
Masson, Serge ;
Bertoli, Elisa ;
Radaelli, Enrico ;
Patroniti, Nicolo ;
Di Lelio, Alessandro ;
Pesenti, Antonio ;
Latini, Roberto .
ANESTHESIOLOGY, 2008, 108 (06) :1037-1046
[3]
ASHBAUGH DG, 1967, LANCET, V2, P319
[4]
CONTINUOUS POSITIVE-PRESSURE BREATHING (CPPB) IN ADULT RESPIRATORY DISTRESS SYNDROME [J].
ASHBAUGH, DG ;
PETTY, TL ;
BIGELOW, DB ;
HARRIS, TM .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1969, 57 (01) :31-&
[5]
ASHBAUGH DG, 1972, SURG GYNECOL OBSTETR, V135, P865
[6]
BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
[7]
The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor [J].
Bastarache, Julie A. ;
Wang, Ling ;
Geiser, Thomas ;
Wang, Zhengming ;
Albertine, Kurt H. ;
Matthay, Michael A. ;
Ware, Lorraine B. .
THORAX, 2007, 62 (07) :608-616
[8]
HIGH-DOSE CORTICOSTEROIDS IN PATIENTS WITH THE ADULT RESPIRATORY-DISTRESS SYNDROME [J].
BERNARD, GR ;
LUCE, JM ;
SPRUNG, CL ;
RINALDO, JE ;
TATE, RM ;
SIBBALD, WJ ;
KARIMAN, K ;
HIGGINS, S ;
BRADLEY, R ;
METZ, CA ;
HARRIS, TR ;
BRIGHAM, KL .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (25) :1565-1570
[9]
THE AMERICAN-EUROPEAN CONSENSUS CONFERENCE ON ARDS - DEFINITIONS, MECHANISMS, RELEVANT OUTCOMES, AND CLINICAL-TRIAL COORDINATION [J].
BERNARD, GR ;
ARTIGAS, A ;
BRIGHAM, KL ;
CARLET, J ;
FALKE, K ;
HUDSON, L ;
LAMY, M ;
LEGALL, JR ;
MORRIS, A ;
SPRAGG, R ;
COCHIN, B ;
LANKEN, PN ;
LEEPER, KV ;
MARINI, J ;
MURRAY, JF ;
OPPENHEIMER, L ;
PESENTI, A ;
REID, L ;
RINALDO, J ;
VILLAR, J ;
VANASBECK, BS ;
DHAINAUT, JF ;
MANCEBO, J ;
MATTHAY, M ;
MEYRICK, B ;
PAYEN, D ;
PERRET, C ;
FOWLER, AA ;
SCHALLER, MD ;
HUDSON, LD ;
HYERS, T ;
KNAUS, W ;
MATTHAY, R ;
PINSKY, M ;
BONE, RC ;
BOSKEN, C ;
JOHANSON, WG ;
LEWANDOWSKI, K ;
REPINE, J ;
RODRIGUEZROISIN, R ;
ROUSSOS, C ;
ANTONELLI, MA ;
BELOUCIF, S ;
BIHARI, D ;
BURCHARDI, H ;
LEMAIRE, F ;
MONTRAVERS, P ;
PETTY, TL ;
ROBOTHAM, J ;
ZAPOL, W .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (03) :818-824
[10]
Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709